Recombinant Glypican-3 Monoclonal Antibody (AN301865L)
-
-
-
- +2
For research use only.
| Verified Samples |
Verified Samples in WB: Raji (-), HepG2 Verified Samples in IHC: Human hepatocellular carcinoma, Human liver(Negative tissue) Verified Samples in IF: HepG2, Raji(Negative cell line) |
| Dilution | WB 1:2000-1:10000, IHC 1:100-1:500, IF 1:50 |
| Isotype | IgG, κ |
| Host | Rabbit |
| Reactivity | Human, |
| Applications | WB, IHC, IF |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Recombinant human Glypican-3 fragment |
| Abbre | Glypican-3 |
| Synonyms | MXR, GPC, UNQ, PRO, CDw, ADAM, Protein FOAP, Secreted glypican, Glypican proteoglycan, Sialic acid-binding Ig-like lectin, C20orf, OCI, GPC3, DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB, SGBS, SGBS1, glypican-3, CDw329, Glypican 3, Glypican proteoglycan 3, Glypican-3 [Precursor], GTR2 2, Heparan sulphate proteoglycan, Intestinal protein OCI 5, Intestinal protein OCI-5, OCI 5, Protein FOAP-9, Secreted glypican-3, Sialic acid-binding Ig-like lectin 9, SIGLEC9, Siglec-9, ADAM33, C20orf153, UNQ873, PRO1891, OCI5 |
| Swissprot | |
| Calculated MW | 70, 40 kDa |
| Observed MW |
15, 70 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Membrane |
| Concentration | 1 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A purified |
| Research Areas | Stem Cells, Signal Transduction, Cancer, Developmental Biology |
| Clone No. | A577 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | Glypican 3 belongs to Glypicans (GPCs), a family of glycosylphosphatidylinositol (GPI)-anchored heparan sulphate proteoglycans (HSPGs) that may play a role in the control of cell division and growth regulation. In mammals, there are six GPCs (GPC1 to GPC6), all of which have a similar core-protein size of approx. 60 kDa and the clustering of glycosaminoglycan attachment site near the C-terminus. They are tethered to the cell surface by GPI linkages, which can be cleaved by endogenous phospholipases, thus releasing the protein. Glypican 3 (GPC3) is highly expressed in many tissues during development and plays an important role in the regulation of embryonic growth. Loss-of-function mutations of GPC3 result in the Simpson-Golabi-Behmel overgrowth syndrome (SGBS), and Gpc-3 null mice display developmental overgrowth. In hepatocellular carcinoma (HCC), the overexpression of glypican 3 has been demonstrated to be a reliable diagnostic indicator. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
